title: Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1+T-cell subsets.
abstract: Monoclonal antibodies specific for programmed cell death 1 (PDCD1, best known as PD-1) have been shown to mediate antineoplastic effects in follicular lymphoma patients. However, the relative proportion of intratumoral PD-1+T-cell subsets, in particular follicular helper T cells (which exert pro-tumor functions) and effector T cells (which have anticancer activity), may impact clinical outcome, and should therefore be carefully considered for patient selection in this setting.
authors.affiliation: Department of Lymphoma and Myeloma; The University of Texas M.D. Anderson Cancer Center; Houston, TX USA ; Center for Cancer Immunology Research; The University of Texas M.D. Anderson Cancer Center; Houston, TX USA.
authors.forename: Fuliang
authors.initials: F
authors.lastname: Chu
authors.affiliation: Department of Lymphoma and Myeloma; The University of Texas M.D. Anderson Cancer Center; Houston, TX USA ; Center for Cancer Immunology Research; The University of Texas M.D. Anderson Cancer Center; Houston, TX USA.
authors.forename: Sattva S
authors.initials: SS
authors.lastname: Neelapu
keywords: PD-1; T cell; clinical trial; lymphoma; rituximab